(Reuters) - A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity. from Reuters: Health News http://ift.tt/2DPIJRY
Post a Comment